Attention-Deficit/Hyperactivity Disorder (ADHD). Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Control group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of placebo (similar components of curc
Treatment - Drugs
Control group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of placebo (similar components of curcumin capsules) t
Intervention group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of curcumin (Sina Drug) twice a day.
Sponsors
Vice Chancellor for Research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Years to 15 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Aged between 7 and 15 years; diagnosis Attention-Deficit/Hyperactivity Disorder (ADHD) based on DSM-V-TR criteria; lack of mental retardation (MR), epilepsy, pervasive developmental disorder, schizophrenia, mania episode, anxiety disorders, bipolar disorder, special ability and learning disorders, and hyperactivity disorder due to organic brain syndrome (OBS) or drug reactions. Exclusion criteria: Liver and renal failure; thyroid disorder; allergy to curcumin; chronic inflammatory diseases; use of anti-inflammatory and antioxidant drugs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation the effectiveness of clinical outcomes including learn, impulsivity, anxiety, hyperactivity and conduct disorder (CD) score. Timepoint: before, 4 and 8 weeks after intervention. Method of measurement: Base on questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzea Ranghian
Mashhad University of Medical Sciences
Outcome results
None listed